The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy

Launched by SIR MORTIMER B. DAVIS - JEWISH GENERAL HOSPITAL · Oct 9, 2015

Keywords

ClinConnect Summary

This clinical trial is studying the ability of certain gene changes, specifically the TMPRSS2-ERG gene fusion and PTEN deletion, to predict how prostate cancer will behave in men who have already experienced a rise in their prostate-specific antigen (PSA) levels after receiving radiation therapy. The researchers want to understand if these genetic factors can help identify which patients are at higher risk for more aggressive cancer.

Men aged 65 to 74 who have a specific type of prostate cancer (T3a or higher), a PSA level greater than 20, and a Gleason score of 8 or higher may be eligible to participate. To join the study, participants need to be in good overall health and agree to take part by signing an informed consent form. Those who enroll can expect to undergo further testing to evaluate these genetic factors and contribute to important research that could impact future treatment options for prostate cancer.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • T3a +
• • PSA \> 20
• • Gleason 8 or higher
• • Karnofsky performance status ≥ 70.
• • Signed study-specific informed consent
• Exclusion Criteria:
• • -